Early Detection of Pancreatic Cancer in Type 2 Diabetes Mellitus Patients Based on 1H NMR Metabolomics
- Lenka MichálkováLenka MichálkováDepartment of Analytical Chemistry, Institute of Chemical Process Fundamentals of the CAS, Prague 6 16502, Czech RepublicDepartment of Analytical Chemistry, University of Chemistry and Technology Prague, Prague 6 16628, Czech RepublicMore by Lenka Michálková,
- Štěpán HorníkŠtěpán HorníkDepartment of Analytical Chemistry, Institute of Chemical Process Fundamentals of the CAS, Prague 6 16502, Czech RepublicDepartment of Analytical Chemistry, University of Chemistry and Technology Prague, Prague 6 16628, Czech RepublicMore by Štěpán Horník,
- Jan Sýkora*Jan Sýkora*Email: [email protected]Department of Analytical Chemistry, Institute of Chemical Process Fundamentals of the CAS, Prague 6 16502, Czech RepublicMore by Jan Sýkora,
- Lucie HabartováLucie HabartováDepartment of Analytical Chemistry, University of Chemistry and Technology Prague, Prague 6 16628, Czech RepublicMore by Lucie Habartová,
- Vladimír SetničkaVladimír SetničkaDepartment of Analytical Chemistry, University of Chemistry and Technology Prague, Prague 6 16628, Czech RepublicMore by Vladimír Setnička, and
- Bohuš Bunganič*Bohuš Bunganič*Email: [email protected]Department of Internal Medicine, 1st Faculty of Medicine of Charles University and Military University Hospital, Prague 6 16902, Czech RepublicMore by Bohuš Bunganič
Abstract
The association of pancreatic cancer with type 2 diabetes mellitus was investigated by 1H NMR metabolomic analysis of blood plasma. Concentration data of 58 metabolites enabled discrimination of pancreatic cancer (PC) patients from healthy controls (HC) and long-term type 2 diabetes mellitus (T2DM) patients. A panel of eight metabolites was proposed and successfully tested for group discrimination. Furthermore, a prediction model for the identification of at-risk individuals for future development of pancreatic cancer was built and tested on recent-onset diabetes mellitus (RODM) patients. Six of 59 RODM samples were assessed as PC with an accuracy of more than 80%. The health condition of these individuals was re-examined, and in four cases, a correlation to the prediction was found. The current health condition can be retrospectively attributed to misdiagnosed pancreatogenic diabetes or to early-stage pancreatic cancer.
Cited By
This article has not yet been cited by other publications.